-
141.发明公开COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GLIOBLASTOMA (GBM) AND OTHER CANCERS 有权肿瘤相关肽和相关抗癌疫苗的组合用于治疗脑胶质瘤（GBM）和其他癌症
公开(公告)号：EP2331118A1
公开(公告)日：2011-06-15
申请号：EP09778749.3
申请日：2009-09-28
发明人： SCHOOR, Oliver , HILF, Norbert , WEINSCHENK, Toni , TRAUTWEIN, Claudia , WALTER, Steffen , SINGH, Harpreet
CPC分类号： A61K39/0011 , A61K35/17 , A61K38/00 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/55588 , A61K2039/572 , A61K2039/605 , A61K2039/6081 , A61K2039/6093 , A61M5/002 , C07K7/06 , C07K7/08 , C07K14/70539 , C07K2319/00 , C07K2319/40 , C12N5/0638 , C12N2501/50 , G01N33/57492 , Y02A50/472
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 25 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
摘要翻译： 本发明涉及免疫治疗肽及其在免疫治疗中的应用，特别是癌症的免疫治疗。 本发明公开了单独或与其他肿瘤相关肽组合的肿瘤相关T辅助细胞肽表位，其作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分。 特别地，本发明的肽的组合物可用于引发针对神经胶质瘤的抗肿瘤免疫应答的疫苗组合物中。
-
142.发明授权T-cell epitopes from the oncofetal antigen-immature laminin receptor protein and medical uses thereof 有权从不成熟Lamininrezeptorprotein（Oncofoetal抗原）和它们的医药用途的T细胞表位
公开(公告)号：EP1717245B1
公开(公告)日：2011-06-08
申请号：EP05009095.0
申请日：2005-04-26
发明人： Zeis, Matthias
CPC分类号： C07K14/4748
-
公开(公告)号：EP2295443A1
公开(公告)日：2011-03-16
申请号：EP10009967.0
申请日：2004-03-23
发明人： Rammensee, Hans-Georg , Stevanovic, Stefan , Weinschenk, Toni , Trautwein, Claudia , Djengjel, Jörn , Schoor, Oliver
CPC分类号： C07K7/06 , A61K38/00 , C07K14/47 , C07K14/4748 , C07K14/78
摘要： Die Erfindung betrifft ein Tumor-assozüertes Peptid mit einer Aminosäuresequenz, die ausgewählt ist aus der Gruppe bestehend aus SEQ ID-Nr. 1 bis SEQ ID-Nr. 101 aus dem beiliegenden Sequenzprotokoll, wobei das Peptid die Fähigkeit aufweist, an ein Molekül des menschlichen Haupt-Histokompatibilitäts-Komplexes (MHC) Klasse-I zu binden. Die Erfindung betrifft darüber hinaus die Verwendung der Peptide und der für die Peptide kodierenden Nukleinsäuren zur Herstellung eines Arzneimittels und zur Behandlung von Tumorerkrankungen und/oder adenomatöser Erkrankungen. Ferner wird eine pharmazeutische Zusammensetzung beschrieben, die mindestens eines der Peptide aufweist.
摘要翻译： 101个特异性肿瘤相关肽（I），可以结合人类主要组织相容性复合体（MHC）I类分子的所有序列都是新的。 还包括：（1）编码（I）的核酸（II）; （2）含有（II）的载体; 和（3）由（II）转基因或（2）的载体产生（I）的细胞。 活动：细胞抑制。 没有给出生物数据。 动作机制：疫苗; 诱导细胞毒性T细胞应答，包括体外诱导，随后向患者施用活化细胞。
-
公开(公告)号：EP2183278A2
公开(公告)日：2010-05-12
申请号：EP08785106.9
申请日：2008-07-25
发明人： SINGH, Harpreet , SCHOOR, Oliver , TRAUTWEIN, Claudia , HILF, Norbert , WEINSCHENK, Toni , WALTER, Steffen , LEWANDROWSKI, Peter
CPC分类号： A61K39/0011 , A61K35/17 , A61K2039/5158 , A61K2039/572 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C07K2317/34 , C07K2319/00 , C12N5/0638 , C12N9/0036 , C12N9/13 , C12N2502/1157 , C12Y208/02011
摘要： The present invention relates to amino acid sequences of peptides derived from tumour associated antigens that are able to bind to MHC complexes of either class, and elicit an immune response, as well as to uses of said peptides for the treatment of diseases.
-
145.发明授权TUMOR-ASSOCIATED PEPTIDES BINDING PROMISCUOUSLY TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS II MOLECULES 有权肿瘤相关肽AN混杂人文LEUKOZYTENANTIGEN-（HLA）II类分子结合
公开(公告)号：EP1922335B1
公开(公告)日：2009-12-09
申请号：EP06791838.3
申请日：2006-09-05
发明人： DENGJEL, Jörn
CPC分类号： C07K14/4748 , A61K38/00 , C07K14/7051
-
146.发明公开Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines 有权肿瘤相关肽的新型制剂结合于免疫接种I或II类的人白细胞抗原
公开(公告)号：EP2111867A1
公开(公告)日：2009-10-28
申请号：EP09005725.8
申请日：2009-04-23
CPC分类号： A61K39/0011 , A61K9/0019 , A61K9/19 , A61K38/08 , A61K38/10 , A61K47/10 , A61K47/26 , A61K2039/55555 , Y10T428/13
摘要： The present invention relates to novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules as vaccines for the use in immunotherapeutic methods. In particular, the present invention relates to formulations for the immunotherapy of cancer, in particular renal and brain cancer, in particular glioma, especially glioblastoma cancer. The present invention furthermore relates to vaccine compositions for eliciting anti-tumour immune responses.
摘要翻译： 本发明涉及肿瘤相关肽结合人白细胞抗原（HLA）I类或II类分子作为疫苗用于免疫治疗方法中的用途的新颖的式灰。 特别地，本发明涉及式灰用于癌症免疫治疗，特别是在尤其是肾和脑肿瘤，神经胶质瘤，爱特别成胶质细胞瘤癌。 本发明进一步更涉及疫苗组合物用于引发抗肿瘤免疫应答。
-
147.发明公开IMMUNOGENIC T-HELPER EPITOPES FROM HUMAN TUMOUR ANTIGENS AND IMMUNOTHERAPEUTIC METHODS USING SAID EPITOPES 有权人类肿瘤抗原的免疫原性T辅助表位和它们在免疫治疗方法
公开(公告)号：EP1794190A2
公开(公告)日：2007-06-13
申请号：EP05778354.0
申请日：2005-09-09
IPC分类号： C07K14/47
CPC分类号： C07K14/4748
摘要： The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular renal cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 338 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
-
148.发明授权Einem Peptid aus Antigen MUC-1 entsprechende DNS zur Auslösung einer Immunreaktion gegen Tumorzellen 有权阿肽抗原MUC-1 DNA对应引发针对肿瘤细胞的免疫应答
公开(公告)号：EP1484397B1
公开(公告)日：2007-01-17
申请号：EP04013790.3
申请日：2000-03-28
发明人： Brossart, Peter, Dr. , Stevanovic, Stefan, Dr. , Brugger, Wolfram, Dr. , Kanz, Lothar, Prof. Dr. , Rammensee, Hans Georg, Prof. Dr.
CPC分类号： C07K14/4727 , A61K39/00 , A61K48/00 , A61K2039/53
-
公开(公告)号：EP1299113A2
公开(公告)日：2003-04-09
申请号：EP01965092.8
申请日：2001-07-09
CPC分类号： A61K38/1709 , Y02A50/473
摘要： The invention relates to the use of gp96 molecules that carry no antigens of interest, for marking and/or activating antigen-presenting cells (APCs), for example dendritic cells, monocytes, macrophages, B cells and peritoneal exudation cells. Said APCs can be loaded with antigens once they have been activated and are used to induce an immune response, or in tumor therapy.
-
公开(公告)号：EP4419079A1
公开(公告)日：2024-08-28
申请号：EP22805823.6
申请日：2022-10-18
CPC分类号： A61K9/08 , A61K47/12 , A61K38/1774
-
-
-
-
-
-
-
-
-
搜索结果
268 条记录 (耗时 0.039 秒)
